m+Medelevator.RU
← Поиск публикаций
Journal of ginseng research · 2026

Therapeutic potential of panax ginseng-derived nanovesicles in osteoporosis through enhanced osteoblast.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lee Sang-Hoon, Kwon Jae-Hee, Kim Hyun-Woo, Mun Se Hwan, Yang Young, Kim Jihoon, Seo Kwang-Won, Kim Do-Kyun, Cho Young-Eun

Аннотация

BACKGROUND: Osteoporosis is a skeletal disorder caused by an imbalance between bone resorption and formation, which leads to reduced bone density and increased fracture risk. Plant-derived nanovesicles have emerged as safe, biocompatible biomaterials with therapeutic potential for bone regeneration.

METHODS: In this work, the biological effects of Panax ginseng-derived nanovesicles (PNVs) were evaluated with a focus on osteoblast differentiation, bone formation, and mineralization. PNVs were successfully isolated, characterized, and tested for their osteogenic capacity using MC3T3-E1 cells, mouse primary osteoblasts, and osteoclasts.

RESULTS: Treatment with PNVs (0-10 μg/mL) for 3 or 7 days markedly promoted osteoblastic maturation and matrix mineral deposition, as confirmed by Alizarin-red and Von Kossa staining. In addition, PNVs exposure upregulated key osteogenic genes, including Runx2, ALP, and OPN, while activating major signaling cascades such as BMP2/4 and phosphorylated p38, implying their involvement in osteogenic regulation. Moreover, in an ovariectomized (OVX) mouse model, oral administration of PNVs improved bone microarchitecture by stimulating osteoblast-driven bone regeneration and attenuating osteoclast-mediated bone degradation.

CONCLUSIONS: Collectively, our findings indicate that PNVs promote osteoblast differentiation and bone matrix formation, thereby enhancing mineralization and demonstrating their potential as a natural nanotherapeutic approach for osteoporosis prevention and treatment.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты